AVPR1B Polyclonal Antibody, PE-Cy5 Conjugated

Vasopressin (AVP), the antidiuretic hormone, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3) . AVP mediates its effects through a family of G-protein coupled receptors, the vasopressin receptors type V1a, V2 and V3 (also designated V1b) (1,2) . The AVP receptor V1a is responsible for several functions, including blood vessel constriction, liver glycogenolysis and platelet adhesion (3) . It is detected as a full length protein and a shorter protein, which results from proteolytic cleavage of its amino terminus (4) . The V1a receptor is coupled to Gq/11 protein, which increases the intracellular calcium concentration (3) . The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5,6) . Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5,7) . The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7) . The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8) . AVP receptor antagonists may have potential therapeutic effects in hypertension, congestive heart failure, nephrotic syndrome and ACTH-secreting tumors (2) .

Antidiuretic hormone receptor 1b; Arginine vasopressin receptor 1B; Arginine vasopressin receptor 3; AVPR V1b; AVPR V3; Avpr1b; AVPR3; Pituitary vasopressin receptor 3; V1bR; V1BR_HUMAN; Vasopressin V1b receptor; Vasopressin V3 receptor; VPR3.